---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-22-000040"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T05:16:43.866233+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moderna Q2 revenue $4.7B, GAAP EPS $5.24, announces $3B buyback, reiterates ~$21B 2022 sales outlook

## Summary
- Q2 revenue $4.7B vs $4.4B YoY; GAAP net income $2.2B ($5.24 diluted EPS) vs $2.8B ($6.46) YoY.
- Board authorizes new $3B share repurchase program; $1.9B used in H1 2022 repurchases.
- 2022 advance purchase agreements for COVID vaccine expected delivery ~$21B; Q4 sales seen > Q3.
- Cost of sales 30% of product sales in Q2, including $499M inventory write-downs and $184M purchase commitment loss.
- Four infectious disease vaccines in Phase 3; proof-of-concept data in rare diseases and immuno-oncology expected H2 2022.

## SEC filing metadata
- accession: 0001682852-22-000040
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285222000040/0001682852-22-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285222000040/mrna-20220803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-22-000040
- JSON: https://secwatch.observer/filing/0001682852-22-000040.json
- Plain text: https://secwatch.observer/filing/0001682852-22-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.